Responses

PDF

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
Publication Date - String

Vertical Tabs

Other responses

  • Published on:
    Adverse events in clinical trials with azathioprine for prevention of postoperative recurrence
    • Hans Herfarth, MD
    • Other Contributors:
      • Christine Tjaden, Milan Lukas, Florian Obermeier, Karin Dilger, Ralph Müller, Jürgen Schölmerich

    Dear Editor,

    We read with great interest the study by Ardizzone et al. (1) and the excellent review of Sands (2) commenting on the efficacy and side effects of azathioprine (AZA) in the therapy of ulcerative colitis. Ardiazonne et al. (1) observed in their investigator blinded study, which included patients with steroid dependent ulcerative colitis, more mild to moderate adverse events (AE) in azathioprine than i...

    Show More
    Conflict of Interest:
    None declared.